AIC
EDIT icon

Ameritas Investment Company’s Editas Medicine EDIT Stock Holding History

Ameritas Investment Company’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150
Closed -$3K – 1192
2018
Q4 		$3K Buy
+150
New +$4.08K ﹤0.01% 1316

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Ameritas Investment Company's EDIT Position: Q1 2019 in Review

Ameritas Investment Company sold out of Editas Medicine (EDIT) in Q1 2019, closing a stake of 150 shares — an estimated $3K sold.

Ameritas Investment Company first reported a position in EDIT in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 201 funds tracked by Wall St. Rank hold EDIT as of Q1 2019.

  • Ameritas Investment Company reported no remaining Editas Medicine position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 150 Editas Medicine shares in Q1 2019, an estimated $3K.
  • Ameritas Investment Company first reported a position in Editas Medicine in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Editas Medicine position peaked at $3K in Q4 2018.
  • 201 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.